Physician profile
Amy I Freeman
NPI 1467448514
$3,352.77
in general payments reported to CMS, 2019-2025
31 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $87.56 · 2021: $105 · 2022: $139 · 2023: $536 · 2024: $360 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,907 · Education: $23.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,906.54 |
| Education | $23.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $430.71 | 2019-2025 | |
| Abbvie INC. | $379.00 | 2021-2025 | |
| Medimetriks Pharmaceuticals, INC. | $350.00 | 2019 | |
| Janssen Biotech, INC. | $321.04 | 2019-2025 | Tremfya, Stelara, Simponi |
| Galderma Laboratories, L.P. | $171.00 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Genzyme Corporation | $136.49 | 2021-2025 | |
| Dermavant Sciences, INC. | $132.58 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $132.44 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $121.48 | 2019-2022 | |
| Incyte Corporation | $117.23 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $114.25 | 2021-2025 | Adbry, Anzupgo |
| Allergan, INC. | $108.93 | 2019-2022 | |
| Lilly USA, LLC | $93.00 | 2019-2025 | Olumiant, Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $91.17 | 2019-2025 | Libtayo, Dupixent |
| Botanix Sb INC | $88.17 | 2025 | Sofdra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $83.36 | 2019-2024 | Winlevi |
| Sandoz INC. | $81.92 | 2019-2020 | |
| Amgen INC. | $79.56 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $66.59 | 2023-2025 | Zoryve |
| Celgene Corporation | $45.50 | 2019-2024 | Sotyktu |
| Sebela Pharmaceuticals INC. | $26.65 | 2019-2023 | Naftin |
| Exact Sciences Corporation | $26.22 | 2025 | The Cologuard Plus Collection Kit |
| Encore Dermatology INC. | $26.16 | 2019 | |
| Krystal Biotech INC | $19.20 | 2025 | Vyjuvek |
| Revance Therapeutics, INC. | $18.97 | 2024 | Daxxify |
| Alexion Pharmaceuticals, INC. | $18.38 | 2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $15.42 | 2023 | Sotyktu |
| Glaxosmithkline, LLC. | $15.28 | 2024 | Nucala |
| Mission Pharmacal Company | $14.29 | 2019 | |
| Vyne Pharmaceuticals INC. | $14.24 | 2020 | |
| Almirall LLC | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.